Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Lori

Showing results (21-30 of 56) with videos related to

Pageof 6
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|October 1, 1993
Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replicationW Y Gao, A Cara, R C Gallo, et al.
Human Gene Therapy|December 1, 1996
Efficacy of antitat gene therapy in the presence of high multiplicity infection and inflammatory cytokinesJ Lisziewicz, D Sun, R C Gallo, et al.
Journal of Clinical Pharmacology|February 1, 1996
Pharmacokinetics of hydroxyurea in patients infected with human immunodeficiency virus type IP Villani, R Maserati, M B Regazzi, et al.
Medical Oncology and Tumor Pharmacotherapy|January 1, 1988
Different distribution of DNA polymerases alpha and beta in bone marrow and peripheral blood from human leukemiaF Lori, A I Scovassi, E Brusamolino, et al.
Human Gene Therapy|April 25, 2000
Combination gene therapy: synergistic inhibition of human immunodeficiency virus Tat and Rev functions by a single RNA moleculeJ Lisziewicz, G Zeng, C Gratas, et al.
Virology|January 10, 1995
Multiple determinants for growth of human immunodeficiency virus type 1 in monocyte-macrophagesA Malykh, M S Reitz, A Louie, et al.
Virology|April 1, 1995
Self-limiting, cell type-dependent replication of an integrase-defective human immunodeficiency virus type 1 in human primary macrophages but not T lymphocytesA Cara, F Guarnaccia, M S Reitz, et al.
AIDS Research and Human Retroviruses|May 20, 1999
Immune restoration by combination of a cytostatic drug (hydroxyurea) and anti-HIV drugs (didanosine and indinavir)F Lori, H Jessen, J Lieberman, et al.
International Journal of Clinical Pharmacology and Therapeutics|October 30, 1999
Hydroxyurea toxicity combined with didanosine (ddl) in HIV-1-seropositive asymptomatic individualsE Seminari, J Lisziewicz, C Tinelli, et al.
Lancet (London, England)|February 16, 2000
Structured treatment interruptions to control HIV-1 infectionF Lori, R Maserati, A Foli, et al.
Pageof 6

Showing results (21-30 of 56) with videos related to

Sort By:
Pageof 6
Proceedings of the National Academy of Sciences of the United States of America|October 1, 1993
Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replicationW Y Gao, A Cara, R C Gallo, et al.
Human Gene Therapy|December 1, 1996
Efficacy of antitat gene therapy in the presence of high multiplicity infection and inflammatory cytokinesJ Lisziewicz, D Sun, R C Gallo, et al.
Journal of Clinical Pharmacology|February 1, 1996
Pharmacokinetics of hydroxyurea in patients infected with human immunodeficiency virus type IP Villani, R Maserati, M B Regazzi, et al.
Medical Oncology and Tumor Pharmacotherapy|January 1, 1988
Different distribution of DNA polymerases alpha and beta in bone marrow and peripheral blood from human leukemiaF Lori, A I Scovassi, E Brusamolino, et al.
Human Gene Therapy|April 25, 2000
Combination gene therapy: synergistic inhibition of human immunodeficiency virus Tat and Rev functions by a single RNA moleculeJ Lisziewicz, G Zeng, C Gratas, et al.
Virology|January 10, 1995
Multiple determinants for growth of human immunodeficiency virus type 1 in monocyte-macrophagesA Malykh, M S Reitz, A Louie, et al.
Virology|April 1, 1995
Self-limiting, cell type-dependent replication of an integrase-defective human immunodeficiency virus type 1 in human primary macrophages but not T lymphocytesA Cara, F Guarnaccia, M S Reitz, et al.
AIDS Research and Human Retroviruses|May 20, 1999
Immune restoration by combination of a cytostatic drug (hydroxyurea) and anti-HIV drugs (didanosine and indinavir)F Lori, H Jessen, J Lieberman, et al.
International Journal of Clinical Pharmacology and Therapeutics|October 30, 1999
Hydroxyurea toxicity combined with didanosine (ddl) in HIV-1-seropositive asymptomatic individualsE Seminari, J Lisziewicz, C Tinelli, et al.
Lancet (London, England)|February 16, 2000
Structured treatment interruptions to control HIV-1 infectionF Lori, R Maserati, A Foli, et al.
Pageof 6